Top Page
JD Health International, Inc.
(6618)
JD Health International, Inc. (6618) vs. iShares MSCI Hong Kong ETF (EWH)
JD Health International, Inc. Business Overview & Revenue Model
JD Health International, Inc. Earnings Call Summary
JD Health International, Inc. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 65.11B | 58.16B | 53.53B | 46.74B | 30.68B | 19.38B |
| Gross Profit | 15.50B | 13.31B | 11.87B | 9.89B | 7.20B | 4.92B |
| EBITDA | 2.49B | 1.31B | 2.93B | -60.93M | -1.37B | 364.50M |
| Net Income | 4.72B | 4.16B | 2.14B | 380.11M | -1.07B | -17.23B |
Balance Sheet | ||||||
| Total Assets | 78.46B | 71.27B | 64.29B | 61.28B | 48.00B | 43.99B |
| Cash, Cash Equivalents and Short-Term Investments | 49.31B | 51.24B | 41.22B | 47.67B | 41.99B | 40.30B |
| Total Debt | 429.69M | 258.39M | 214.75M | 199.41M | 201.27M | 89.98M |
| Total Liabilities | 20.48B | 16.03B | 14.92B | 16.49B | 8.15B | 4.74B |
| Stockholders Equity | 57.97B | 55.23B | 49.36B | 44.78B | 39.85B | 39.25B |
Cash Flow | ||||||
| Free Cash Flow | 8.32B | 4.29B | 4.54B | 5.86B | 2.93B | 3.68B |
| Operating Cash Flow | 8.35B | 4.33B | 4.60B | 5.91B | 3.43B | 3.70B |
| Investing Cash Flow | 7.96B | 3.15B | -8.02B | -4.24B | -17.75B | -7.84B |
| Financing Cash Flow | -54.11M | -45.61M | -117.20M | -925.45M | -163.65M | 32.03B |
JD Health International, Inc. Technical Analysis
JD Health International, Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | HK$200.09B | 38.69 | 8.52% | ― | 18.56% | 79.54% | |
| ― | HK$662.10M | 8.02 | 5.33% | 8.08% | 0.47% | 50.46% | |
| ― | HK$1.61B | 5.59 | 20.47% | 4.41% | -3.56% | -17.45% | |
| ― | HK$7.02B | 18.86 | 14.86% | 2.66% | 16.41% | 32.97% | |
| ― | HK$8.26B | 16.80 | 6.78% | ― | -13.92% | -36.32% | |
| ― | HK$6.97B | -6.69 | -9.67% | 2.39% | -8.56% | -403.12% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
JD Health International, Inc. Corporate Events
JD Health International, Inc. announced the grant of 299,090 Award Shares to its employees under the Post-IPO Share Award Scheme, representing about 0.01% of the total issued shares. This initiative aims to align employee interests with the company’s growth and profitability, encouraging long-term contributions. The shares will vest over periods ranging from 0.25 to 4 years, with no performance targets attached, and include a clawback mechanism to protect the company’s interests. This move is expected to strengthen employee retention and commitment, potentially impacting the company’s operational efficiency and market positioning positively.
The most recent analyst rating on (HK:6618) stock is a Buy with a HK$78.50 price target. To see the full list of analyst forecasts on JD Health International, Inc. stock, see the HK:6618 Stock Forecast page.
JD Health International Inc. has announced the composition of its board of directors, highlighting the roles and functions of its executive, non-executive, and independent non-executive directors. This announcement provides insights into the company’s governance structure, potentially impacting its strategic direction and stakeholder confidence.
The most recent analyst rating on (HK:6618) stock is a Buy with a HK$78.50 price target. To see the full list of analyst forecasts on JD Health International, Inc. stock, see the HK:6618 Stock Forecast page.
JD Health International, Inc. announced amendments to its existing agreements with JD.com, including changes to the Promotional Campaign Services Framework Agreement and the Shared Services Framework Agreement. The company has set new annual caps for these agreements for the year ending December 31, 2025, and has renewed the agreements for a three-year term starting January 1, 2026. These transactions are considered continuing connected transactions under the Listing Rules, with some requiring compliance with specific provisions. The company has also received a waiver from strict compliance with certain listing rule requirements, indicating strategic adjustments in its operational agreements with JD.com, which could impact its market positioning and stakeholder relationships.
The most recent analyst rating on (HK:6618) stock is a Buy with a HK$78.50 price target. To see the full list of analyst forecasts on JD Health International, Inc. stock, see the HK:6618 Stock Forecast page.
JD Health International Inc. announced significant changes in its board of directors and remuneration committee. Mr. Enlin Jin and Mr. Qingqing Yi have resigned from their positions due to personal and professional commitments, respectively. Mr. Dong Cao has been appointed as the new executive director and CEO, bringing extensive experience from his previous roles within the JD Group. These changes are expected to impact the company’s strategic direction and governance, potentially influencing its market positioning and stakeholder relations.
The most recent analyst rating on (HK:6618) stock is a Buy with a HK$78.50 price target. To see the full list of analyst forecasts on JD Health International, Inc. stock, see the HK:6618 Stock Forecast page.
JD Health International Inc. has announced the composition of its board of directors, which includes executive, non-executive, and independent non-executive directors. The board is structured with three committees: audit, remuneration, and nomination, each with designated chairpersons and members. This announcement underscores the company’s commitment to robust governance and strategic oversight, potentially impacting its operational efficiency and stakeholder confidence.
The most recent analyst rating on (HK:6618) stock is a Buy with a HK$78.50 price target. To see the full list of analyst forecasts on JD Health International, Inc. stock, see the HK:6618 Stock Forecast page.
JD Health International, Inc. recently held its earnings call, showcasing a robust performance with a positive outlook. The company reported significant revenue growth and an increase in active users, alongside advancements in AI applications and healthcare service innovations. Despite a slight rise in selling and marketing expenses, the overall sentiment remains optimistic, reflecting a strong trajectory for JD Health.
JD Health International, Inc. announced its interim results for the first half of 2025, reporting significant financial growth with a 24.5% increase in revenue to RMB35.3 billion and a 27.4% rise in profit to RMB2.59 billion. The company has improved its healthcare offerings and advanced AI-enhanced service models, reinforcing its leading position in the healthcare market and addressing the growing demand for high-quality healthcare services. The company’s strategic focus on AI and health consumption aligns with China’s policies promoting high-quality healthcare development, further solidifying its market position.
The most recent analyst rating on (HK:6618) stock is a Buy with a HK$56.00 price target. To see the full list of analyst forecasts on JD Health International, Inc. stock, see the HK:6618 Stock Forecast page.
JD Health International Inc. has announced a board meeting scheduled for August 14, 2025, to approve and publish its unaudited interim results for the first half of 2025. The meeting will also consider the recommendation for an interim dividend. The company will host a conference call on the same day to discuss these results, indicating a proactive approach in engaging with stakeholders and maintaining transparency in its financial operations.
The most recent analyst rating on (HK:6618) stock is a Buy with a HK$31.00 price target. To see the full list of analyst forecasts on JD Health International, Inc. stock, see the HK:6618 Stock Forecast page.